ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1649724
Comparative Plasma Metabolomics of Delta and Omicron SARS-CoV-2 Variants: Insights into Variant-Specific Pathogenesis and Therapeutic Implications
Provisionally accepted
- 1Department of Critical Care, Cumming School of Medicine, University of Calgary, Calgary, Canada
- 2Departments of Medicine and Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Canada
- 3Department of Biomedical Engineering, Schulich School of Engineering, University of Calgary, Calgary, Canada
- 4Department of Mathematics and Statistics, Faculty of Science, University of Calgary, Calgary, Calgary, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The emergence of SARS-CoV-2 led to a global pandemic. Delta and Omicron, classified as concerning variants, differ significantly in transmissibility, disease severity, and antibody neutralization. Delta is associated with more severe disease, whereas Omicron is linked to increased transmissibility yet milder disease. This study investigates plasma metabolomic differences between Delta and Omicron infections and their associations with disease severity and treatment response. Importantly, this work examines variant-specific treatment metabolic effects -an aspect that remains underexplored despite the ongoing evolution of SARS-CoV-2 variants -and thus begins to fill a critical gap in the literature.Methods: A total of 109 hospitalized SARS-CoV-2 patients, confirmed by RT-PCR positivity (53 Delta, 56 Omicron), were matched by age and sex. Plasma samples collected on hospitalization days 1, 2, and 7 were analyzed using DI/LC-MS/MS-based (direct injection, liquid chromatography-tandem mass-spectrometry) targeted metabolomics. We employed univariate and multivariate statistical and pathway analyses to investigate and characterize metabolomic differences.Results: Distinct metabolic profiles differentiated Delta and Omicron infections. Specific metabolites, including tyrosine, asparagine, leucine, and acylcarnitines (C3, C4, C5), significantly distinguished variants and severity groups. Delta infections showed higher associations with severe outcomes. Corticosteroid treatment influenced metabolic profiles, revealing associations with modulation of metabolic and clinical responses.This study reveals significant plasma-based metabolic differences between Delta and Omicron SARS-CoV-2 variants, potentially reflecting their distinct clinical outcomes and severities.
Keywords: COVID - 19, SARS-C0V-2, delta, omicron, Metabolomics, severity, Treatment
Received: 18 Jun 2025; Accepted: 22 Sep 2025.
Copyright: © 2025 Winston, Pimentel, Banoei and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Brent W Winston, bwinston@ucalgary.ca
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.